Top

Published in:

01-12-2021 | Breast Cancer | Research article

Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study

Authors: Anna H. Wu, Adrian A. Franke, Lynne R. Wilkens, Chiuchen Tseng, Shannon M. Conroy, Yuqing Li, Linda M. Polfus, Mindy De Rouen, Christian Caberto, Christopher Haiman, Daniel O. Stram, Loïc Le Marchand, Iona Cheng

Published in: Breast Cancer Research | Issue 1/2021

Abstract

Background

The epidemiologic evidence from observational studies on breast cancer risk and phthalates, endocrine disrupting chemicals, has been inconsistent. In the only previous study based on pre-diagnostic urinary phthalates and risk of breast cancer, results were null in mostly white women.

Methods

We examined the association between pre-diagnostic urinary phthalates and breast cancer in a nested case-control study within the Multiethnic Cohort (MEC) study, presenting the first data from five major racial/ethnic groups in the USA. We measured 10 phthalate metabolites and phthalic acid, using a sensitive liquid chromatography mass spectrometry assay on 1032 women with breast cancer (48 African Americans, 77 Latinos, 155 Native Hawaiians, 478 Japanese Americans, and 274 Whites) and 1030 matched controls. Conditional logistic regression was used to examine risk with individual metabolites and ratios of primary (MEHP, mono-2-ethylhexyl-phthalate) to secondary (MEHHP, mono(2-ethyl-5-hydroxyhexyl); MEOHP, mono(2-ethyl-5-oxohexy)) metabolites of di-2-ethylhexyl phthalate (DEHP), a widely used plasticizer. In addition, we investigated risk associations with high (∑HMWP) and low molecular weight (∑LMWP) phthalates, as well as total phthalates which included high and low molecular weight phthalates with phthalic acid (∑LMHMPA) or without phthalic acid in molar ratios (∑LMHM_molar) and adjusted for creatinine and potential confounders.

Results

Among all women, breast cancer risk was higher for those in tertile 2 and tertile 3 of primary to secondary metabolites of DEHP (MEHP/(MEHHP + MEOHP)) in comparison to those in tertile 1; the respective odds ratios were 1.32 (95% CI 1.04–1.68) and 1.26 (95% CI 0.96–1.66) (P_trend = 0.05). Risk among Native Hawaiian women increased with exposures to eight of ten individual phthalates and total phthalates (∑LMHMPA OR_{T3 vs T1} = 2.66, 95% CI 1.39–5.12, P_trend = 0.001). In analysis by hormone receptor (HR) status, exposure above the median of ∑LMWP was associated with an increased risk of HR-positive breast cancer (OR = 1.30, 95% CI 1.05–1.60) while above the median exposure to phthalic acid was associated with an increased risk of HR-negative breast cancer (OR_{above vs below median} = 1.59, 95% CI 1.01–2.48).

Conclusions

Further investigations of suggestive associations of elevated breast cancer risk with higher ratios of primary to secondary metabolites of DEHP, and differences in risk patterns by race/ethnicity and HR status are warranted.

Available only for authorised users

Wang Y, Zhu H, Kannan K. A review of biomonitoring of phthalate exposures. Toxics. 2019;7(2):21. https://doi.org/10.3390/toxics7020021.

Silva MJ, Malek NA, Hodge CC, Reidy JA, Kato K, Barr DB, Needham LL, Brock JW. Improved quantitative detection of 11 urinary phthalate metabolites in humans using liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;789(2):393–404. https://doi.org/10.1016/S1570-0232(03)00164-8.CrossRefPubMed

Rodgers KM, Udesky JO, Rudel RA, Brody JG. Environmental chemicals and breast cancer: an updated review of epidemiological literature informed by biological mechanisms. Environ Res. 2018;160:152–82. https://doi.org/10.1016/j.envres.2017.08.045.CrossRefPubMed

Woodruff TJ. Bridging epidemiology and model organisms to increase understanding of endocrine disrupting chemicals and human health effects. J Steroid Biochem Mol Biol. 2011;127(1–2):108–17. https://doi.org/10.1016/j.jsbmb.2010.11.007.CrossRefPubMed

Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, Brock JW, Needham LL, Calafat AM. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. Environ Health Perspect. 2004;112(3):331–8.CrossRef

Liu X, Cao YF, Ran RX, Dong PP, Gonzalez FJ, Wu X, Huang T, Chen JX, Fu ZW, Li RS, Liu YZ, Sun HZ, Fang ZZ. New insights into the risk of phthalates: inhibition of UDP-glucuronosyltransferases. Chemosphere. 2016;144:1966–72. https://doi.org/10.1016/j.chemosphere.2015.10.076.CrossRefPubMed

Frederiksen H, Skakkebaek NE, Andersson AM. Metabolism of phthalates in humans. Mol Nutr Food Res. 2007;51(7):899–911. https://doi.org/10.1002/mnfr.200600243.CrossRefPubMed

Morgan M, Deoraj A, Felty Q, Roy D. Environmental estrogen-like endocrine disrupting chemicals and breast cancer. Mol Cell Endocrinol. 2017;457:89–102. https://doi.org/10.1016/j.mce.2016.10.003.CrossRefPubMed

Fabjan E, Hulzebos E, Mennes W, Piersma AH. A category approach for reproductive effects of phthalates. Crit Rev Toxicol. 2006;36(9):695–726. https://doi.org/10.1080/10408440600894914.CrossRefPubMed

10.

Brody JG, Rudel RA. Environmental pollutants and breast cancer. Environ Health Perspect. 2003;111(8):1007–19. https://doi.org/10.1289/ehp.6310.CrossRefPubMedPubMedCentral

11.

Lopez-Carrillo L, Hernandez-Ramirez RU, Calafat AM, Torres-Sanchez L, Galvan-Portillo M, Needham LL, Ruiz-Ramos R, Cebrian ME. Exposure to phthalates and breast cancer risk in northern Mexico. Environ Health Perspect. 2010;118(4):539–44. https://doi.org/10.1289/ehp.0901091.CrossRefPubMed

12.

Holmes AK, Koller KR, Kieszak SM, Sjodin A, Calafat AM, Sacco FD, Varner DW, Lanier AP, Rubin CH. Case-control study of breast cancer and exposure to synthetic environmental chemicals among Alaska native women. Int J Circumpolar Health. 2014;73(1):25760. https://doi.org/10.3402/ijch.v73.25760.CrossRefPubMed

13.

Parada H Jr, Gammon MD, Chen J, Calafat AM, Neugut AI, Santella RM, Wolff MS, Teitelbaum SL. Urinary phthalate metabolite concentrations and breast cancer incidence and survival following breast cancer: the Long Island Breast Cancer Study Project. Environ Health Perspect. 2018;126(4):047013. https://doi.org/10.1289/EHP2083.CrossRefPubMedPubMedCentral

14.

Reeves KW, Diaz Santana M, Manson JE, Hankinson SE, Zoeller RT, Bigelow C, Sturgeon SR, Spiegelman D, Tinker L, Luo J, et al. Urinary phthalate biomarker concentrations and postmenopausal breast cancer risk. J Natl Cancer Inst. 2019;111(10):1059–67. https://doi.org/10.1093/jnci/djz002.CrossRefPubMedPubMedCentral

15.

Ahern TP, Broe A, Lash TL, Cronin-Fenton DP, Ulrichsen SP, Christiansen PM, Cole BF, Tamimi RM, Sorensen HT, Damkier P. Phthalate exposure and breast cancer incidence: a Danish nationwide cohort study. J Clin Oncol. 2019;37(21):1800–9. https://doi.org/10.1200/JCO.18.02202.CrossRefPubMedPubMedCentral

16.

Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151(4):346–57. https://doi.org/10.1093/oxfordjournals.aje.a010213.CrossRefPubMedPubMedCentral

17.

Epplein M, Franke AA, Cooney RV, Morris JS, Wilkens LR, Goodman MT, Murphy SP, Henderson BE, Kolonel LN, Le Marchand L. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiol Biomark Prev. 2009;18(7):1962–70. https://doi.org/10.1158/1055-9965.EPI-09-0003.CrossRef

18.

Derby KS, Cuthrell K, Caberto C, Carmella SG, Franke AA, Hecht SS, Murphy SE, Le Marchand L. Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomark Prev. 2008;17(12):3526–35. https://doi.org/10.1158/1055-9965.EPI-08-0424.CrossRef

19.

Song Y, Hauser R, Hu FB, Franke AA, Liu S, Sun Q. Urinary concentrations of bisphenol A and phthalate metabolites and weight change: a prospective investigation in US women. Int J Obes. 2014;38(12):1532–7. https://doi.org/10.1038/ijo.2014.63.CrossRef

20.

Sun Q, Cornelis MC, Townsend MK, Tobias DK, Eliassen AH, Franke AA, Hauser R, Hu FB. Association of urinary concentrations of bisphenol A and phthalate metabolites with risk of type 2 diabetes: a prospective investigation in the Nurses’ Health Study (NHS) and NHSII cohorts. Environ Health Perspect. 2014;122(6):616–23. https://doi.org/10.1289/ehp.1307201.CrossRefPubMedPubMedCentral

21.

Bang du Y, Lee IK, Lee BM: Toxicological characterization of phthalic acid. Toxicol Res 2011, 27(4):191–203.

22.

Albro PW, Jordan S, Corbett JT, Schroeder JL. Determination of total phthalate in urine by gas chromatography. Anal Chem. 1984;56(2):247–50. https://doi.org/10.1021/ac00266a029.CrossRefPubMed

23.

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. https://doi.org/10.1080/00273171.2011.568786.CrossRefPubMedPubMedCentral

24.

Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150(4):327–33. https://doi.org/10.1093/oxfordjournals.aje.a010011.CrossRefPubMed

25.

Conroy SM, Shariff-Marco S, Yang J, Hertz A, Cockburn M, Shvetsov YB, Clarke CA, Abright CL, Haiman CA, Le Marchand L, et al. Characterizing the neighborhood obesogenic environment in the Multiethnic Cohort: a multi-level infrastructure for cancer health disparities research. Cancer Causes Control. 2018;29(1):167–83. https://doi.org/10.1007/s10552-017-0980-1.CrossRefPubMed

26.

Harmon BE, Boushey CJ, Shvetsov YB, Ettienne R, Reedy J, Wilkens LR, Le Marchand L, Henderson BE, Kolonel LN. Associations of key diet-quality indexes with mortality in the Multiethnic Cohort: the Dietary Patterns Methods Project. Am J Clin Nutr. 2015;101(3):587–97. https://doi.org/10.3945/ajcn.114.090688.CrossRefPubMedPubMedCentral

27.

Silva MJ, Samandar E, Preau JL Jr, Needham LL, Calafat AM. Urinary oxidative metabolites of di(2-ethylhexyl) phthalate in humans. Toxicology. 2006;219(1–3):22–32. https://doi.org/10.1016/j.tox.2005.10.018.CrossRefPubMed

28.

Koch HM, Bolt HM, Preuss R, Angerer J. New metabolites of di(2-ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP. Arch Toxicol. 2005;79(7):367–76. https://doi.org/10.1007/s00204-004-0642-4.CrossRefPubMed

29.

Hauser R. Urinary phthalate metabolites and semen quality: a review of a potential biomarker of susceptibility. Int J Androl. 2008;31(2):112–7. https://doi.org/10.1111/j.1365-2605.2007.00844.x.CrossRefPubMed

30.

Yaghjyan L, Sites S, Ruan Y, Chang SH. Associations of urinary phthalates with body mass index, waist circumference and serum lipids among females: National Health and Nutrition Examination Survey 1999-2004. Int J Obes. 2015;39(6):994–1000. https://doi.org/10.1038/ijo.2015.8.CrossRef

31.

Chen FP, Chien MH. Lower concentrations of phthalates induce proliferation in human breast cancer cells. Climacteric. 2014;17(4):377–84. https://doi.org/10.3109/13697137.2013.865720.CrossRefPubMed

32.

Chen FP, Chien MH, Chen HY, Ng YT. Effects of phthalates on normal human breast cells co-cultured with different fibroblasts. PLoS One. 2018;13(6):e0199596. https://doi.org/10.1371/journal.pone.0199596.CrossRefPubMedPubMedCentral

33.

Hsieh TH, Tsai CF, Hsu CY, Kuo PL, Hsi E, Suen JL, Hung CH, Lee JN, Chai CY, Wang SC, Tsai EM. n-Butyl benzyl phthalate promotes breast cancer progression by inducing expression of lymphoid enhancer factor 1. PLoS One. 2012;7(8):e42750. https://doi.org/10.1371/journal.pone.0042750.CrossRefPubMedPubMedCentral

34.

Picard K, Lhuguenot JC, Lavier-Canivenc MC, Chagnon MC. Estrogenic activity and metabolism of n-butyl benzyl phthalate in vitro: identification of the active molecule(s). Toxicol Appl Pharmacol. 2001;172(2):108–18. https://doi.org/10.1006/taap.2001.9141.CrossRefPubMed

35.

Okubo T, Suzuki T, Yokoyama Y, Kano K, Kano I. Estimation of estrogenic and anti-estrogenic activities of some phthalate diesters and monoesters by MCF-7 cell proliferation assay in vitro. Biol Pharm Bull. 2003;26(8):1219–24. https://doi.org/10.1248/bpb.26.1219.CrossRefPubMed

36.

Erkekoglu P, Rachidi W, Yuzugullu OG, Giray B, Favier A, Ozturk M, Hincal F. Evaluation of cytotoxicity and oxidative DNA damaging effects of di(2-ethylhexyl)-phthalate (DEHP) and mono(2-ethylhexyl)-phthalate (MEHP) on MA-10 Leydig cells and protection by selenium. Toxicol Appl Pharmacol. 2010;248(1):52–62. https://doi.org/10.1016/j.taap.2010.07.016.CrossRefPubMed

37.

Meeker JD, Calafat AM, Hauser R. Di(2-ethylhexyl) phthalate metabolites may alter thyroid hormone levels in men. Environ Health Perspect. 2007;115(7):1029–34. https://doi.org/10.1289/ehp.9852.CrossRefPubMedPubMedCentral

38.

Hauser R, Meeker JD, Singh NP, Silva MJ, Ryan L, Duty S, Calafat AM. DNA damage in human sperm is related to urinary levels of phthalate monoester and oxidative metabolites. Hum Reprod. 2007;22(3):688–95. https://doi.org/10.1093/humrep/del428.CrossRefPubMed

39.

Ferguson KK, Loch-Caruso R, Meeker JD. Urinary phthalate metabolites in relation to biomarkers of inflammation and oxidative stress: NHANES 1999-2006. Environ Res. 2011;111(5):718–26. https://doi.org/10.1016/j.envres.2011.02.002.CrossRefPubMedPubMedCentral

40.

Kang SC, Lee BM. DNA methylation of estrogen receptor alpha gene by phthalates. J Toxicol Environ Health A. 2005;68(23–24):1995–2003. https://doi.org/10.1080/15287390491008913.CrossRefPubMed

41.

Townsend MK, Franke AA, Li X, Hu FB, Eliassen AH. Within-person reproducibility of urinary bisphenol A and phthalate metabolites over a 1 to 3 year period among women in the Nurses’ Health Studies: a prospective cohort study. Environ Health. 2013;12(1):80. https://doi.org/10.1186/1476-069X-12-80.CrossRefPubMedPubMedCentral

Title: Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study
Authors: Anna H. Wu
Adrian A. Franke
Lynne R. Wilkens
Chiuchen Tseng
Shannon M. Conroy
Yuqing Li
Linda M. Polfus
Mindy De Rouen
Christian Caberto
Christopher Haiman
Daniel O. Stram
Loïc Le Marchand
Iona Cheng
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-021-01419-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Robust inflammatory breast cancer gene signature using nonparametric random forest analysis

Sole adjuvant intraoperative breast radiotherapy in Taiwan: a single-center experience

Early-life exposures and age at thelarche in the Sister Study cohort

Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study

Biomarkers of mammographic density in premenopausal women

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly

Keynote webinar | Spotlight on antibody–drug conjugates in cancer